Market Research Report
Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2019
|Published by||DelveInsight Business Research LLP||Product code||914447|
|Published||Content info||60 Pages
Delivery time: 1-2 business days
|Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2019|
|Published: October 1, 2019||Content info: 60 Pages||
"Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines. The assessment part of the report embraces, in depth Intrahepatic Cholangiocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intrahepatic Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Intrahepatic Cholangiocarcinoma (ICC) originated from the liver parenchyma beyond the second order bile ducts and belongs to a family of aggressive Cholangiocarcinomas, a rare and heterogeneous malignant neoplasm with epithelial cell of biliary duct and has the histologic and biochemical features of cholangiocyte differentiation. Receptor tyrosine kinases such as IL-6 receptor, c-MET, and the EGFR family members ERBB2 and ERBB1 are key signaling pathways in ICC. Aberrant activation of these receptor tyrosine kinases causes constitutive activation of downstream signaling cascades (i.e., JAK/ STAT3, PI3K/Akt, ERK1/2, and p38MAPK) resulting in dysregulation of cell senescence, cell cycle regulation and proliferation, and apoptosis. Common symptoms of ICC include malaise, cachexia, abdominal pain, night sweats, fatigue and/or jaundice, associated or not with systemic manifestations, etc. The risk factors for developing ICC includes Primary sclerosing cholangitis, parasitic infections, intrahepatic biliary stones (hepatolithiasis), liver cirrhosis, viral infection, and others. The recently proposed classification of ICCs subdivided the tumors into conventional, bile ductular, or intraductal neoplasm type, or rare variants (combined hepatocellular ICC, undifferentiated ICC, squamous/adenosquamous type). The conventional type include a small duct or peripheral type and large duct or perihilar type. The bile ductular and combined hepatocellular-ICC might have originated from hepatic progenitor cells (HPCs) (as a neural cell adhesion molecule, a marker of HPC has been detected).
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Intrahepatic Cholangiocarcinoma targeted therapeutics development with respective active and dormant or discontinued projects. Intrahepatic Cholangiocarcinoma pipeline report covers 17+ companies. Some of the key players include Delcath Systems (Melphalan/HDS), Sirnaomics (STP705), RedHill Biopharma (Opaganib), etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
To be continued in the report…………………………